Atossa Therapeutics (ATOS) vs aTyr Pharma (ATYR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
aTyr Pharma (ATYR) has outperformed Atossa Therapeutics (ATOS) over the past year, losing 74.5% versus a loss of 85.5%. Over five years, ATOS leads with a -94.4% price change compared with -97.1% for ATYR. Atossa Therapeutics is the larger company by market cap ($24.3 million vs $24.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATOS | ATYR |
|---|---|---|
| Share price | $2.44 | $0.2481 |
| Market cap | $24.35M | $24.34M |
| 1-day change | +0.84% | -2.82% |
| YTD return | -72.66% | -67.39% |
| 1-year return | -85.47% | -74.47% |
| 5-year return | -94.36% | -97.07% |
| EPS (TTM) | $-4.45 | $-0.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.00 | $1.12 |
| 52-week low | $1.70 | $0.246 |
| Distance from 52-week high | -86.44% | -77.85% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +678.69% | +1052.76% |
| Average volume | 63.48K | 3.24M |
| Shares outstanding | 9.98M | 98.09M |
| Employees | 16 | 58 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ATYR has outperformed ATOS by 11.0 percentage points over the past year.
About Atossa Therapeutics
ATOS stock →Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
About aTyr Pharma
ATYR stock →aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 58 employees
ATOS vs ATYR FAQ
Which is bigger, Atossa Therapeutics or aTyr Pharma?
Atossa Therapeutics (ATOS) is larger, with a market capitalization of $24.35M compared with $24.34M for aTyr Pharma (ATYR).
Which stock has performed better over the past year, ATOS or ATYR?
ATYR returned -74.47% over the past 12 months, compared with -85.47% for ATOS (price return, excluding dividends). Past performance does not predict future results.
Are Atossa Therapeutics and aTyr Pharma in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Atossa Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for aTyr Pharma.